nodes	percent_of_prediction	percent_of_DWPC	metapath
Gonadorelin—Peritoneal haemorrhage—Sunitinib—pancreatic cancer	0.0707	0.123	CcSEcCtD
Gonadorelin—Abortion spontaneous—Fluorouracil—pancreatic cancer	0.0343	0.0597	CcSEcCtD
Gonadorelin—Menopause—Tamoxifen—pancreatic cancer	0.0303	0.0527	CcSEcCtD
Gonadorelin—Ovarian cyst—Tamoxifen—pancreatic cancer	0.0282	0.049	CcSEcCtD
Gonadorelin—Pentagastrin—CCKBR—pancreatic cancer	0.0273	0.532	CrCbGaD
Gonadorelin—Ceruletide—CCKAR—pancreatic cancer	0.0232	0.453	CrCbGaD
Gonadorelin—GNRHR—Peptide GPCRs—SSTR3—pancreatic cancer	0.0159	0.0426	CbGpPWpGaD
Gonadorelin—GNRHR—Peptide GPCRs—SSTR1—pancreatic cancer	0.0152	0.0408	CbGpPWpGaD
Gonadorelin—GNRHR—Peptide GPCRs—SSTR2—pancreatic cancer	0.0147	0.0393	CbGpPWpGaD
Gonadorelin—GNRHR—Peptide GPCRs—CCKBR—pancreatic cancer	0.0142	0.0379	CbGpPWpGaD
Gonadorelin—GNRHR—GPCRs, Other—SSTR2—pancreatic cancer	0.0124	0.0333	CbGpPWpGaD
Gonadorelin—Congenital anomaly—Fluorouracil—pancreatic cancer	0.0122	0.0213	CcSEcCtD
Gonadorelin—Developmental delay—Fluorouracil—pancreatic cancer	0.0122	0.0213	CcSEcCtD
Gonadorelin—GNRHR—GPCRs, Other—CCKBR—pancreatic cancer	0.012	0.0321	CbGpPWpGaD
Gonadorelin—Pelvic pain—Tamoxifen—pancreatic cancer	0.0113	0.0197	CcSEcCtD
Gonadorelin—Embolism—Tamoxifen—pancreatic cancer	0.0107	0.0186	CcSEcCtD
Gonadorelin—GNRHR—Peptide GPCRs—CCKAR—pancreatic cancer	0.0106	0.0283	CbGpPWpGaD
Gonadorelin—Redness—Tamoxifen—pancreatic cancer	0.0102	0.0177	CcSEcCtD
Gonadorelin—Haematoma—Sunitinib—pancreatic cancer	0.00937	0.0163	CcSEcCtD
Gonadorelin—Embolism—Sunitinib—pancreatic cancer	0.00918	0.016	CcSEcCtD
Gonadorelin—Breast pain—Tamoxifen—pancreatic cancer	0.00788	0.0137	CcSEcCtD
Gonadorelin—Contusion—Tamoxifen—pancreatic cancer	0.00788	0.0137	CcSEcCtD
Gonadorelin—Embolism—Irinotecan—pancreatic cancer	0.00756	0.0131	CcSEcCtD
Gonadorelin—Thromboembolism—Epirubicin—pancreatic cancer	0.00712	0.0124	CcSEcCtD
Gonadorelin—GNRHR—Peptide GPCRs—AGTR1—pancreatic cancer	0.0071	0.019	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—CCKBR—pancreatic cancer	0.00675	0.0181	CbGpPWpGaD
Gonadorelin—Thromboembolism—Doxorubicin—pancreatic cancer	0.00658	0.0115	CcSEcCtD
Gonadorelin—GNRHR—GPCRs, Other—CNR1—pancreatic cancer	0.00654	0.0175	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—CCKBR—pancreatic cancer	0.00604	0.0162	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—PRLHR—pancreatic cancer	0.0059	0.0158	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—GAST—pancreatic cancer	0.00581	0.0155	CbGpPWpGaD
Gonadorelin—Swelling—Tamoxifen—pancreatic cancer	0.00566	0.00984	CcSEcCtD
Gonadorelin—GNRHR—G alpha (q) signalling events—CCK—pancreatic cancer	0.00525	0.0141	CbGpPWpGaD
Gonadorelin—Embolism—Docetaxel—pancreatic cancer	0.00523	0.00909	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GAST—pancreatic cancer	0.00519	0.0139	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—CCKAR—pancreatic cancer	0.00503	0.0135	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—SSTR3—pancreatic cancer	0.00502	0.0134	CbGpPWpGaD
Gonadorelin—Redness—Docetaxel—pancreatic cancer	0.00497	0.00864	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—SSTR1—pancreatic cancer	0.00481	0.0129	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—PPY—pancreatic cancer	0.00472	0.0126	CbGpPWpGaD
Gonadorelin—Injection site reaction—Gemcitabine—pancreatic cancer	0.0047	0.00817	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—CCK—pancreatic cancer	0.0047	0.0126	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—SSTR2—pancreatic cancer	0.00463	0.0124	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—CCKAR—pancreatic cancer	0.0045	0.012	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—PRLHR—pancreatic cancer	0.00449	0.012	CbGpPWpGaD
Gonadorelin—Embolism venous—Epirubicin—pancreatic cancer	0.00448	0.0078	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCKBR—pancreatic cancer	0.00447	0.012	CbGpPWpGaD
Gonadorelin—Embolism venous—Doxorubicin—pancreatic cancer	0.00415	0.00722	CcSEcCtD
Gonadorelin—Abdominal discomfort—Tamoxifen—pancreatic cancer	0.00414	0.0072	CcSEcCtD
Gonadorelin—Swelling—Fluorouracil—pancreatic cancer	0.00382	0.00665	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—SSTR3—pancreatic cancer	0.00382	0.0102	CbGpPWpGaD
Gonadorelin—Pelvic pain—Epirubicin—pancreatic cancer	0.00372	0.00647	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—SSTR1—pancreatic cancer	0.00366	0.0098	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—PPY—pancreatic cancer	0.00359	0.00961	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—GCG—pancreatic cancer	0.00355	0.00949	CbGpPWpGaD
Gonadorelin—Abdominal discomfort—Sunitinib—pancreatic cancer	0.00354	0.00616	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—SSTR2—pancreatic cancer	0.00353	0.00944	CbGpPWpGaD
Gonadorelin—Embolism—Epirubicin—pancreatic cancer	0.00352	0.00613	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCK—pancreatic cancer	0.00348	0.00931	CbGpPWpGaD
Gonadorelin—Pelvic pain—Doxorubicin—pancreatic cancer	0.00344	0.00599	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Sunitinib—pancreatic cancer	0.00344	0.00597	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—CCKBR—pancreatic cancer	0.00341	0.00911	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CNR2—pancreatic cancer	0.00339	0.00907	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—AGTR1—pancreatic cancer	0.00338	0.00905	CbGpPWpGaD
Gonadorelin—Redness—Epirubicin—pancreatic cancer	0.00335	0.00583	CcSEcCtD
Gonadorelin—Injection site reaction—Docetaxel—pancreatic cancer	0.00334	0.0058	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCKAR—pancreatic cancer	0.00333	0.00892	CbGpPWpGaD
Gonadorelin—Embolism—Doxorubicin—pancreatic cancer	0.00326	0.00567	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GCG—pancreatic cancer	0.00317	0.00849	CbGpPWpGaD
Gonadorelin—Redness—Doxorubicin—pancreatic cancer	0.0031	0.00539	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—pancreatic cancer	0.00303	0.0081	CbGpPWpGaD
Gonadorelin—Erythema—Tamoxifen—pancreatic cancer	0.00301	0.00523	CcSEcCtD
Gonadorelin—Erythema—Erlotinib—pancreatic cancer	0.00298	0.00517	CcSEcCtD
Gonadorelin—Flatulence—Erlotinib—pancreatic cancer	0.00293	0.0051	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Irinotecan—pancreatic cancer	0.00283	0.00492	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—SCT—pancreatic cancer	0.00278	0.00743	CbGpPWpGaD
Gonadorelin—Swelling—Docetaxel—pancreatic cancer	0.00276	0.0048	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Fluorouracil—pancreatic cancer	0.00271	0.00471	CcSEcCtD
Gonadorelin—Angiopathy—Sunitinib—pancreatic cancer	0.00268	0.00467	CcSEcCtD
Gonadorelin—Immune system disorder—Sunitinib—pancreatic cancer	0.00267	0.00465	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—CCK—pancreatic cancer	0.00265	0.00709	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—SST—pancreatic cancer	0.00264	0.00705	CbGpPWpGaD
Gonadorelin—Breast pain—Epirubicin—pancreatic cancer	0.00259	0.00451	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—GLP1R—pancreatic cancer	0.00258	0.00691	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—CNR2—pancreatic cancer	0.00258	0.00691	CbGpPWpGaD
Gonadorelin—Erythema—Sunitinib—pancreatic cancer	0.00258	0.00448	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—CCKAR—pancreatic cancer	0.00254	0.00679	CbGpPWpGaD
Gonadorelin—Flatulence—Sunitinib—pancreatic cancer	0.00254	0.00441	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CNR1—pancreatic cancer	0.00243	0.00651	CbGpPWpGaD
Gonadorelin—Breast pain—Doxorubicin—pancreatic cancer	0.0024	0.00417	CcSEcCtD
Gonadorelin—Shock—Erlotinib—pancreatic cancer	0.00239	0.00415	CcSEcCtD
Gonadorelin—Nervous system disorder—Erlotinib—pancreatic cancer	0.00238	0.00414	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—SHH—pancreatic cancer	0.00231	0.00619	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PRLHR—pancreatic cancer	0.00231	0.00617	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—IAPP—pancreatic cancer	0.00229	0.00612	CbGpPWpGaD
Gonadorelin—Injection site reaction—Epirubicin—pancreatic cancer	0.00225	0.00391	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGTR1—pancreatic cancer	0.00224	0.006	CbGpPWpGaD
Gonadorelin—Angiopathy—Irinotecan—pancreatic cancer	0.00221	0.00385	CcSEcCtD
Gonadorelin—Immune system disorder—Irinotecan—pancreatic cancer	0.0022	0.00383	CcSEcCtD
Gonadorelin—Breast disorder—Docetaxel—pancreatic cancer	0.0022	0.00383	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—PTHLH—pancreatic cancer	0.00219	0.00587	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—PTCH1—pancreatic cancer	0.00219	0.00587	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—SSTR3—pancreatic cancer	0.00216	0.00578	CbGpPWpGaD
Gonadorelin—Angiopathy—Gemcitabine—pancreatic cancer	0.00215	0.00375	CcSEcCtD
Gonadorelin—Immune system disorder—Gemcitabine—pancreatic cancer	0.00214	0.00373	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.00212	0.00368	CcSEcCtD
Gonadorelin—Fatigue—Tamoxifen—pancreatic cancer	0.00212	0.00368	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—GDI1—pancreatic cancer	0.00211	0.00566	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GDI2—pancreatic cancer	0.00211	0.00566	CbGpPWpGaD
Gonadorelin—Pain—Tamoxifen—pancreatic cancer	0.0021	0.00365	CcSEcCtD
Gonadorelin—Constipation—Tamoxifen—pancreatic cancer	0.0021	0.00365	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.0021	0.00365	CcSEcCtD
Gonadorelin—Fatigue—Erlotinib—pancreatic cancer	0.00209	0.00364	CcSEcCtD
Gonadorelin—Flatulence—Irinotecan—pancreatic cancer	0.00209	0.00364	CcSEcCtD
Gonadorelin—Injection site reaction—Doxorubicin—pancreatic cancer	0.00208	0.00362	CcSEcCtD
Gonadorelin—Pain—Erlotinib—pancreatic cancer	0.00208	0.00361	CcSEcCtD
Gonadorelin—Constipation—Erlotinib—pancreatic cancer	0.00208	0.00361	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—SSTR1—pancreatic cancer	0.00207	0.00554	CbGpPWpGaD
Gonadorelin—Shock—Sunitinib—pancreatic cancer	0.00207	0.0036	CcSEcCtD
Gonadorelin—Erythema—Gemcitabine—pancreatic cancer	0.00207	0.00359	CcSEcCtD
Gonadorelin—Nervous system disorder—Sunitinib—pancreatic cancer	0.00206	0.00359	CcSEcCtD
Gonadorelin—Erythema—Fluorouracil—pancreatic cancer	0.00203	0.00353	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—PPY—pancreatic cancer	0.00203	0.00543	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—SST—pancreatic cancer	0.00201	0.00537	CbGpPWpGaD
Gonadorelin—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.00201	0.00349	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—SSTR2—pancreatic cancer	0.00199	0.00533	CbGpPWpGaD
Gonadorelin—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.00199	0.00345	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—SSTR3—pancreatic cancer	0.00196	0.00525	CbGpPWpGaD
Gonadorelin—Abdominal pain—Tamoxifen—pancreatic cancer	0.00194	0.00337	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—CCKBR—pancreatic cancer	0.00192	0.00515	CbGpPWpGaD
Gonadorelin—Abdominal pain—Erlotinib—pancreatic cancer	0.00192	0.00334	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—SSTR1—pancreatic cancer	0.00188	0.00503	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—CNR1—pancreatic cancer	0.00185	0.00496	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PPY—pancreatic cancer	0.00184	0.00493	CbGpPWpGaD
Gonadorelin—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.00181	0.00316	CcSEcCtD
Gonadorelin—Fatigue—Sunitinib—pancreatic cancer	0.00181	0.00315	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—SSTR2—pancreatic cancer	0.00181	0.00484	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Tamoxifen—pancreatic cancer	0.00181	0.00314	CcSEcCtD
Gonadorelin—Constipation—Sunitinib—pancreatic cancer	0.0018	0.00313	CcSEcCtD
Gonadorelin—Pain—Sunitinib—pancreatic cancer	0.0018	0.00313	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—GCG—pancreatic cancer	0.00179	0.00479	CbGpPWpGaD
Gonadorelin—Asthenia—Tamoxifen—pancreatic cancer	0.00176	0.00306	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—CCKBR—pancreatic cancer	0.00175	0.00468	CbGpPWpGaD
Gonadorelin—Asthenia—Erlotinib—pancreatic cancer	0.00174	0.00303	CcSEcCtD
Gonadorelin—Pruritus—Tamoxifen—pancreatic cancer	0.00174	0.00302	CcSEcCtD
Gonadorelin—Anaphylactic shock—Irinotecan—pancreatic cancer	0.00173	0.00301	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.00172	0.00299	CcSEcCtD
Gonadorelin—Pruritus—Erlotinib—pancreatic cancer	0.00172	0.00299	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—AGTR1—pancreatic cancer	0.00171	0.00457	CbGpPWpGaD
Gonadorelin—Shock—Irinotecan—pancreatic cancer	0.0017	0.00296	CcSEcCtD
Gonadorelin—Nervous system disorder—Irinotecan—pancreatic cancer	0.0017	0.00295	CcSEcCtD
Gonadorelin—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.00169	0.00293	CcSEcCtD
Gonadorelin—Diarrhoea—Tamoxifen—pancreatic cancer	0.00168	0.00292	CcSEcCtD
Gonadorelin—Abdominal pain—Sunitinib—pancreatic cancer	0.00166	0.00289	CcSEcCtD
Gonadorelin—Diarrhoea—Erlotinib—pancreatic cancer	0.00166	0.00289	CcSEcCtD
Gonadorelin—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.00166	0.00288	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—GAST—pancreatic cancer	0.00166	0.00443	CbGpPWpGaD
Gonadorelin—Nervous system disorder—Gemcitabine—pancreatic cancer	0.00165	0.00288	CcSEcCtD
Gonadorelin—Nervous system disorder—Fluorouracil—pancreatic cancer	0.00163	0.00283	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—SCT—pancreatic cancer	0.00157	0.0042	CbGpPWpGaD
Gonadorelin—Vomiting—Tamoxifen—pancreatic cancer	0.00156	0.00271	CcSEcCtD
Gonadorelin—Hypersensitivity—Sunitinib—pancreatic cancer	0.00155	0.00269	CcSEcCtD
Gonadorelin—Vomiting—Erlotinib—pancreatic cancer	0.00154	0.00269	CcSEcCtD
Gonadorelin—Headache—Tamoxifen—pancreatic cancer	0.00154	0.00267	CcSEcCtD
Gonadorelin—Angiopathy—Docetaxel—pancreatic cancer	0.00153	0.00266	CcSEcCtD
Gonadorelin—Immune system disorder—Docetaxel—pancreatic cancer	0.00152	0.00265	CcSEcCtD
Gonadorelin—Headache—Erlotinib—pancreatic cancer	0.00152	0.00265	CcSEcCtD
Gonadorelin—Asthenia—Sunitinib—pancreatic cancer	0.00151	0.00262	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—GAST—pancreatic cancer	0.0015	0.00402	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—CCK—pancreatic cancer	0.0015	0.004	CbGpPWpGaD
Gonadorelin—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.00149	0.0026	CcSEcCtD
Gonadorelin—Fatigue—Irinotecan—pancreatic cancer	0.00149	0.0026	CcSEcCtD
Gonadorelin—Pruritus—Sunitinib—pancreatic cancer	0.00149	0.00259	CcSEcCtD
Gonadorelin—Breast disorder—Epirubicin—pancreatic cancer	0.00148	0.00258	CcSEcCtD
Gonadorelin—Constipation—Irinotecan—pancreatic cancer	0.00148	0.00258	CcSEcCtD
Gonadorelin—Pain—Irinotecan—pancreatic cancer	0.00148	0.00258	CcSEcCtD
Gonadorelin—Erythema—Docetaxel—pancreatic cancer	0.00147	0.00255	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—CNR2—pancreatic cancer	0.00146	0.0039	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—GLP1R—pancreatic cancer	0.00146	0.0039	CbGpPWpGaD
Gonadorelin—Nausea—Tamoxifen—pancreatic cancer	0.00146	0.00254	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.00146	0.00253	CcSEcCtD
Gonadorelin—Fatigue—Gemcitabine—pancreatic cancer	0.00145	0.00253	CcSEcCtD
Gonadorelin—Constipation—Gemcitabine—pancreatic cancer	0.00144	0.00251	CcSEcCtD
Gonadorelin—Pain—Gemcitabine—pancreatic cancer	0.00144	0.00251	CcSEcCtD
Gonadorelin—Nausea—Erlotinib—pancreatic cancer	0.00144	0.00251	CcSEcCtD
Gonadorelin—Diarrhoea—Sunitinib—pancreatic cancer	0.00144	0.0025	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—CCKAR—pancreatic cancer	0.00143	0.00384	CbGpPWpGaD
Gonadorelin—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.00143	0.00249	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—SCT—pancreatic cancer	0.00142	0.00381	CbGpPWpGaD
Gonadorelin—Pain—Fluorouracil—pancreatic cancer	0.00142	0.00247	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.00142	0.00246	CcSEcCtD
Gonadorelin—Breast disorder—Doxorubicin—pancreatic cancer	0.00137	0.00239	CcSEcCtD
Gonadorelin—Abdominal pain—Irinotecan—pancreatic cancer	0.00137	0.00238	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—PRLHR—pancreatic cancer	0.00136	0.00365	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—CCK—pancreatic cancer	0.00136	0.00364	CbGpPWpGaD
Gonadorelin—Vomiting—Sunitinib—pancreatic cancer	0.00134	0.00232	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—CNR2—pancreatic cancer	0.00132	0.00354	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—GLP1R—pancreatic cancer	0.00132	0.00354	CbGpPWpGaD
Gonadorelin—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.00132	0.00229	CcSEcCtD
Gonadorelin—Headache—Sunitinib—pancreatic cancer	0.00132	0.00229	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—CCKAR—pancreatic cancer	0.0013	0.00349	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—IAPP—pancreatic cancer	0.00129	0.00346	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ACVR1B—pancreatic cancer	0.00128	0.00343	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ZNRF3—pancreatic cancer	0.00128	0.00343	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Irinotecan—pancreatic cancer	0.00128	0.00222	CcSEcCtD
Gonadorelin—Nausea—Sunitinib—pancreatic cancer	0.00125	0.00217	CcSEcCtD
Gonadorelin—Asthenia—Irinotecan—pancreatic cancer	0.00124	0.00216	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—PTHLH—pancreatic cancer	0.00124	0.00332	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00122	0.00212	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.00122	0.00212	CcSEcCtD
Gonadorelin—Asthenia—Gemcitabine—pancreatic cancer	0.00121	0.0021	CcSEcCtD
Gonadorelin—Anaphylactic shock—Docetaxel—pancreatic cancer	0.0012	0.00208	CcSEcCtD
Gonadorelin—Pruritus—Gemcitabine—pancreatic cancer	0.00119	0.00208	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—SHH—pancreatic cancer	0.00119	0.00318	CbGpPWpGaD
Gonadorelin—Diarrhoea—Irinotecan—pancreatic cancer	0.00118	0.00206	CcSEcCtD
Gonadorelin—Shock—Docetaxel—pancreatic cancer	0.00118	0.00205	CcSEcCtD
Gonadorelin—Nervous system disorder—Docetaxel—pancreatic cancer	0.00117	0.00204	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—IAPP—pancreatic cancer	0.00117	0.00314	CbGpPWpGaD
Gonadorelin—Pruritus—Fluorouracil—pancreatic cancer	0.00117	0.00204	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—SSTR3—pancreatic cancer	0.00116	0.0031	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—DTX1—pancreatic cancer	0.00116	0.0031	CbGpPWpGaD
Gonadorelin—Diarrhoea—Gemcitabine—pancreatic cancer	0.00115	0.00201	CcSEcCtD
Gonadorelin—Diarrhoea—Fluorouracil—pancreatic cancer	0.00113	0.00197	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—SST—pancreatic cancer	0.00113	0.00304	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PTHLH—pancreatic cancer	0.00113	0.00301	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PTCH1—pancreatic cancer	0.00113	0.00301	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—pancreatic cancer	0.00111	0.00298	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—SSTR1—pancreatic cancer	0.00111	0.00297	CbGpPWpGaD
Gonadorelin—Vomiting—Irinotecan—pancreatic cancer	0.0011	0.00191	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—PPY—pancreatic cancer	0.00109	0.00291	CbGpPWpGaD
Gonadorelin—Headache—Irinotecan—pancreatic cancer	0.00108	0.00189	CcSEcCtD
Gonadorelin—Vomiting—Gemcitabine—pancreatic cancer	0.00107	0.00187	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—SSTR2—pancreatic cancer	0.00107	0.00286	CbGpPWpGaD
Gonadorelin—Headache—Gemcitabine—pancreatic cancer	0.00106	0.00184	CcSEcCtD
Gonadorelin—Vomiting—Fluorouracil—pancreatic cancer	0.00105	0.00183	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—CNR1—pancreatic cancer	0.00105	0.0028	CbGpPWpGaD
Gonadorelin—Headache—Fluorouracil—pancreatic cancer	0.00104	0.00181	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.00103	0.0018	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—CCKBR—pancreatic cancer	0.00103	0.00276	CbGpPWpGaD
Gonadorelin—Fatigue—Docetaxel—pancreatic cancer	0.00103	0.00179	CcSEcCtD
Gonadorelin—Angiopathy—Epirubicin—pancreatic cancer	0.00103	0.00179	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—SST—pancreatic cancer	0.00103	0.00276	CbGpPWpGaD
Gonadorelin—Nausea—Irinotecan—pancreatic cancer	0.00103	0.00179	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.00103	0.00275	CbGpPWpGaD
Gonadorelin—Immune system disorder—Epirubicin—pancreatic cancer	0.00103	0.00179	CcSEcCtD
Gonadorelin—Pain—Docetaxel—pancreatic cancer	0.00102	0.00178	CcSEcCtD
Gonadorelin—Constipation—Docetaxel—pancreatic cancer	0.00102	0.00178	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pancreatic cancer	0.00101	0.00271	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—GCG—pancreatic cancer	0.00101	0.00271	CbGpPWpGaD
Gonadorelin—Nausea—Gemcitabine—pancreatic cancer	0.001	0.00174	CcSEcCtD
Gonadorelin—Erythema—Epirubicin—pancreatic cancer	0.000989	0.00172	CcSEcCtD
Gonadorelin—Nausea—Fluorouracil—pancreatic cancer	0.000985	0.00171	CcSEcCtD
Gonadorelin—GNRHR—G alpha (q) signalling events—PIK3CA—pancreatic cancer	0.000984	0.00263	CbGpPWpGaD
Gonadorelin—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000979	0.0017	CcSEcCtD
Gonadorelin—Flatulence—Epirubicin—pancreatic cancer	0.000975	0.0017	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—GLI1—pancreatic cancer	0.000971	0.0026	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—DTX4—pancreatic cancer	0.000971	0.0026	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000964	0.00258	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—pancreatic cancer	0.000958	0.00256	CbGpPWpGaD
Gonadorelin—Angiopathy—Doxorubicin—pancreatic cancer	0.000954	0.00166	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—CNR1—pancreatic cancer	0.000951	0.00254	CbGpPWpGaD
Gonadorelin—Immune system disorder—Doxorubicin—pancreatic cancer	0.00095	0.00165	CcSEcCtD
Gonadorelin—Abdominal pain—Docetaxel—pancreatic cancer	0.000946	0.00165	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000944	0.00253	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—NRP1—pancreatic cancer	0.000944	0.00253	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—GCG—pancreatic cancer	0.000918	0.00246	CbGpPWpGaD
Gonadorelin—Erythema—Doxorubicin—pancreatic cancer	0.000915	0.00159	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—HEY2—pancreatic cancer	0.000909	0.00243	CbGpPWpGaD
Gonadorelin—Flatulence—Doxorubicin—pancreatic cancer	0.000902	0.00157	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—GAST—pancreatic cancer	0.000888	0.00238	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Docetaxel—pancreatic cancer	0.000882	0.00153	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	0.00088	0.00235	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—AGTR1—pancreatic cancer	0.000876	0.00234	CbGpPWpGaD
Gonadorelin—Asthenia—Docetaxel—pancreatic cancer	0.000859	0.00149	CcSEcCtD
Gonadorelin—Pruritus—Docetaxel—pancreatic cancer	0.000847	0.00147	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—SCT—pancreatic cancer	0.000842	0.00225	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HEY1—pancreatic cancer	0.000842	0.00225	CbGpPWpGaD
Gonadorelin—Diarrhoea—Docetaxel—pancreatic cancer	0.000819	0.00142	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	0.000814	0.00218	CbGpPWpGaD
Gonadorelin—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000807	0.0014	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—CCK—pancreatic cancer	0.000803	0.00215	CbGpPWpGaD
Gonadorelin—Shock—Epirubicin—pancreatic cancer	0.000794	0.00138	CcSEcCtD
Gonadorelin—Nervous system disorder—Epirubicin—pancreatic cancer	0.000792	0.00138	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—CNR2—pancreatic cancer	0.000782	0.00209	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GLP1R—pancreatic cancer	0.000782	0.00209	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—CXCL8—pancreatic cancer	0.000782	0.00209	CbGpPWpGaD
Gonadorelin—Desmopressin—PTGS2—pancreatic cancer	0.00077	0.015	CrCbGaD
Gonadorelin—GNRHR—Signaling Pathways—CCKAR—pancreatic cancer	0.00077	0.00206	CbGpPWpGaD
Gonadorelin—Vomiting—Docetaxel—pancreatic cancer	0.000761	0.00132	CcSEcCtD
Gonadorelin—Headache—Docetaxel—pancreatic cancer	0.00075	0.0013	CcSEcCtD
Gonadorelin—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000747	0.0013	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—JAG2—pancreatic cancer	0.000746	0.002	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MEN1—pancreatic cancer	0.000736	0.00197	CbGpPWpGaD
Gonadorelin—Shock—Doxorubicin—pancreatic cancer	0.000735	0.00128	CcSEcCtD
Gonadorelin—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000733	0.00127	CcSEcCtD
Gonadorelin—Nausea—Docetaxel—pancreatic cancer	0.000711	0.00124	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—SHH—pancreatic cancer	0.000702	0.00188	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—NOTCH4—pancreatic cancer	0.000697	0.00187	CbGpPWpGaD
Gonadorelin—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000697	0.00121	CcSEcCtD
Gonadorelin—Fatigue—Epirubicin—pancreatic cancer	0.000696	0.00121	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—IAPP—pancreatic cancer	0.000693	0.00185	CbGpPWpGaD
Gonadorelin—Constipation—Epirubicin—pancreatic cancer	0.00069	0.0012	CcSEcCtD
Gonadorelin—Pain—Epirubicin—pancreatic cancer	0.00069	0.0012	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—PTHLH—pancreatic cancer	0.000665	0.00178	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PTCH1—pancreatic cancer	0.000665	0.00178	CbGpPWpGaD
Gonadorelin—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.00066	0.00115	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000645	0.00112	CcSEcCtD
Gonadorelin—Fatigue—Doxorubicin—pancreatic cancer	0.000644	0.00112	CcSEcCtD
Gonadorelin—Constipation—Doxorubicin—pancreatic cancer	0.000639	0.00111	CcSEcCtD
Gonadorelin—Pain—Doxorubicin—pancreatic cancer	0.000639	0.00111	CcSEcCtD
Gonadorelin—Abdominal pain—Epirubicin—pancreatic cancer	0.000638	0.00111	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000611	0.00106	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—SST—pancreatic cancer	0.000608	0.00163	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.0006	0.00161	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—JAG1—pancreatic cancer	0.000595	0.00159	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Epirubicin—pancreatic cancer	0.000595	0.00103	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—NOTCH3—pancreatic cancer	0.000593	0.00159	CbGpPWpGaD
Gonadorelin—Abdominal pain—Doxorubicin—pancreatic cancer	0.000591	0.00103	CcSEcCtD
Gonadorelin—Asthenia—Epirubicin—pancreatic cancer	0.000579	0.00101	CcSEcCtD
Gonadorelin—Pruritus—Epirubicin—pancreatic cancer	0.000571	0.000993	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—CNR1—pancreatic cancer	0.000562	0.0015	CbGpPWpGaD
Gonadorelin—Diarrhoea—Epirubicin—pancreatic cancer	0.000552	0.000961	CcSEcCtD
Gonadorelin—Hypersensitivity—Doxorubicin—pancreatic cancer	0.00055	0.000957	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000545	0.00146	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GCG—pancreatic cancer	0.000542	0.00145	CbGpPWpGaD
Gonadorelin—Asthenia—Doxorubicin—pancreatic cancer	0.000536	0.000932	CcSEcCtD
Gonadorelin—Pruritus—Doxorubicin—pancreatic cancer	0.000528	0.000919	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000528	0.00141	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—AGTR1—pancreatic cancer	0.000517	0.00138	CbGpPWpGaD
Gonadorelin—Vomiting—Epirubicin—pancreatic cancer	0.000513	0.000893	CcSEcCtD
Gonadorelin—Diarrhoea—Doxorubicin—pancreatic cancer	0.000511	0.000889	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—STK11—pancreatic cancer	0.00051	0.00136	CbGpPWpGaD
Gonadorelin—Headache—Epirubicin—pancreatic cancer	0.000506	0.00088	CcSEcCtD
Gonadorelin—Nausea—Epirubicin—pancreatic cancer	0.00048	0.000834	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—PIK3CD—pancreatic cancer	0.000479	0.00128	CbGpPWpGaD
Gonadorelin—Vomiting—Doxorubicin—pancreatic cancer	0.000475	0.000826	CcSEcCtD
Gonadorelin—Headache—Doxorubicin—pancreatic cancer	0.000468	0.000814	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.00046	0.00123	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—SMAD4—pancreatic cancer	0.000447	0.0012	CbGpPWpGaD
Gonadorelin—Nausea—Doxorubicin—pancreatic cancer	0.000444	0.000772	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—CXCL8—pancreatic cancer	0.000442	0.00118	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HES1—pancreatic cancer	0.000436	0.00117	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PIK3CB—pancreatic cancer	0.000418	0.00112	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—CXCL8—pancreatic cancer	0.000401	0.00107	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TERT—pancreatic cancer	0.000382	0.00102	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HIF1A—pancreatic cancer	0.000365	0.000978	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TSC2—pancreatic cancer	0.000365	0.000975	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—APOE—pancreatic cancer	0.000357	0.000955	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—KDR—pancreatic cancer	0.000349	0.000935	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—NFKBIA—pancreatic cancer	0.000332	0.000889	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—NOTCH1—pancreatic cancer	0.000329	0.000881	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PIK3CG—pancreatic cancer	0.000322	0.000861	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—NRAS—pancreatic cancer	0.000322	0.000861	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—EGF—pancreatic cancer	0.000318	0.000852	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—EGFR—pancreatic cancer	0.000293	0.000785	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PIK3CD—pancreatic cancer	0.000283	0.000757	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—PIK3CA—pancreatic cancer	0.00028	0.00075	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—KRAS—pancreatic cancer	0.000277	0.000741	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PIK3CA—pancreatic cancer	0.000255	0.000681	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PIK3CB—pancreatic cancer	0.000247	0.00066	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CXCL8—pancreatic cancer	0.000237	0.000634	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—HRAS—pancreatic cancer	0.000236	0.00063	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—AKT1—pancreatic cancer	0.000229	0.000613	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CASP3—pancreatic cancer	0.000227	0.000607	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CCND1—pancreatic cancer	0.000221	0.000591	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CTNNB1—pancreatic cancer	0.000219	0.000585	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MMP9—pancreatic cancer	0.000214	0.000574	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PTEN—pancreatic cancer	0.000213	0.00057	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—AKT1—pancreatic cancer	0.000208	0.000556	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—SRC—pancreatic cancer	0.000198	0.000529	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—VEGFA—pancreatic cancer	0.000193	0.000515	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—STAT3—pancreatic cancer	0.000191	0.00051	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—NRAS—pancreatic cancer	0.00019	0.000509	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MYC—pancreatic cancer	0.000177	0.000474	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TGFB1—pancreatic cancer	0.000177	0.000473	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—EGFR—pancreatic cancer	0.000173	0.000464	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—KRAS—pancreatic cancer	0.000164	0.000438	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PIK3CA—pancreatic cancer	0.00015	0.000402	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TP53—pancreatic cancer	0.000145	0.000389	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HRAS—pancreatic cancer	0.000139	0.000372	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—AKT1—pancreatic cancer	0.000123	0.000329	CbGpPWpGaD
